Daniel Chober
Overview
Explore the profile of Daniel Chober including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Bremen K, Parczewski M, Monin M, Leszczyszyn-Pynka M, Schlabe S, Lenkiewicz F, et al.
Pathogens
. 2024 Aug;
13(8).
PMID: 39204222
War in Ukraine prompted an enormous refugee influx into Europe, including approximately 4200 people with HIV. The unique healthcare features of Ukrainian refugees living with HIV were compared between two...
2.
Parczewski M, Kufel J, Aksak-Was B, Piwnik J, Chober D, Puzio T, et al.
J Med Virol
. 2023 May;
95(5):e28787.
PMID: 37219059
Introduction: During COVID-19 pandemic, artificial neural network (ANN) systems have been providing aid for clinical decisions. However, to achieve optimal results, these models should link multiple clinical data points to...
3.
Chober D, Czajkowski Z, Aksak-Was B, Dalewska-Kucharczyk K, Holubczak K, Karasinska-Milchert S, et al.
Int J Infect Dis
. 2022 Sep;
124:143-151.
PMID: 36152957
Objectives: Possible immunomodulatory effect of amantadine in patients treated in intensive care unit (ICU), mostly among patients with brain injuries or vascular diseases was observed in several studies. The potential...
4.
Aksak-Was B, Kowalska J, Zabek P, Serwin K, Rafalska-Kosior M, Golab J, et al.
HIV Med
. 2022 Sep;
24(3):325-334.
PMID: 36054430
Introduction: In recent years, a reduction in the life expectancy gap between people living with HIV (PLWH) and the general population has been observed, irrespective of CD4 lymphocyte count, due...
5.
Aksak-Was B, Chober D, Serwin K, Scheibe K, Niscigorska-Olsen J, Niedzwiedz A, et al.
J Inflamm Res
. 2022 Sep;
15:4907-4920.
PMID: 36046662
Introduction: Remdesivir is the first agent with proven clinical efficacy against coronavirus disease 2019 (COVID-19); however, its benefit is associated with early use, and its efficacy has been poorly studied...
6.
Chober D, Aksak-Was B, Niscigorska-Olsen J, Niekrasz M, Parczewski M
Biomedicines
. 2022 Jul;
10(7).
PMID: 35884886
Introduction: Thromboembolic events, including mainly pulmonary embolisms and ischemic strokes, occur in up to one-third of COVID-19 patients. As efficacy of tocilizumab (TCZ) among patients with acute pulmonary embolism (PE)...
7.
Chober D, Aksak-Was B, Bobrek-Lesiakowska K, Budny-Finster A, Holda E, Miezynska-Kurtycz J, et al.
J Clin Med
. 2022 May;
11(9).
PMID: 35566412
Introduction: Acute lung injury is associated with dysfunctional immune response to SARS-CoV-2. This leads to CRS, which require immunomodulatory treatments aiming to limit the excessive production of cytokines. The literature...
8.
Aksak-Was B, Urbanska A, Scheibe K, Serwin K, Leszczyszyn-Pynka M, Rafalska-Kosior M, et al.
J Clin Med
. 2022 Apr;
11(7).
PMID: 35407496
Introduction: Immune restoration is a key clinical aspect that is pursued in the care of human immunodeficiency virus (HIV)-infected patients. Despite effective antiretroviral treatment and undetectable viremia, immune recovery is...
9.
Aksak-Was B, Urbanska A, Leszczyszyn-Pynka M, Chober D, Parczewski M
Infect Genet Evol
. 2021 Dec;
97:105180.
PMID: 34896288
Introduction: Late presentation into care remains a significant problem in the diagnosis of HIV infection, and may negatively impact the Joint United Nations Program HIV/AIDS elimination targets. Host genetics affects...